Risk factors

What each company says could go wrong in its 10-K, and what changed since last year: the risks added, dropped and rewritten.

7,688 annual reports · 4,011 companies

Readings are automated and can be wrong; check the filing for the exact wording.

Older filings

Page 543 of 641 · 7,688 filings

  • Shoals Technologies Group (SHLS) FY2024 10-K risk factors
    31 risks

    This is a new filing with no prior year comparison.

    Filed Feb 25, 2025
  • Si-Bone (SIBN) FY2024 10-K risk factors
    70 risks

    SI-BONE faces ongoing operating losses with an accumulated deficit of $431.4 million as of December 31, 2024. The company relies heavily on third-party suppliers like RMS for key implants and faces intense pricing and reimbursement pressures. Operations are subject to stringent FDA regulations and the adoption risks of the iFuse family of implants.

    Filed Feb 25, 2025
  • Stabilis Solutions (SLNG) FY2024 10-K risk factors
    47 risks

    Stabilis Solutions faces heavy operational, regulatory, and supply chain risks in marketing and delivering LNG across North America.

    Filed Feb 25, 2025
  • SLR Investment (SLRC) FY2024 10-K risk factors
    86 risks

    SLR Investment Corp invests primarily in leveraged middle-market senior secured loans and financing leases. The portfolio is non-diversified and features below investment grade and covenant-lite debt. Leverage, capital access, and key personnel drive operational results.

    Filed Feb 25, 2025
  • Shutterstock (SSTK) FY2024 10-K risk factors
    55 risks

    Shutterstock faces significant transition risks driven by pending merger activities, integration challenges, and potential debt obligations.

    Filed Feb 25, 2025
  • Supernus Pharmaceuticals (SUPN) FY2024 10-K risk factors
    72 risks

    This is a new filing without prior year risk factors. The risk profile is dominated by reliance on three major distributors for product sales, competition from generic drug manufacturers, and regulatory dependencies for product approvals and post-marketing commitments.

    Filed Feb 25, 2025
  • Tarsus Pharmaceuticals (TARS) FY2024 10-K risk factors
    66 risks

    Tarsus relies heavily on the commercial success of its sole approved product, XDEMVY, for Demodex blepharitis. The company faces significant financial risks requiring additional capital, intellectual property challenges, and strict regulatory oversight across manufacturing and clinical trials.

    Filed Feb 25, 2025
  • Tetra Technologies (TTI) FY2024 10-K risk factors
    31 risks

    Oil and gas market sensitivity and customer capital spending drive core operational risks for Tetra Technologies. Low carbon energy initiatives and Arkansas brine lithium extraction anchor long-term strategy risks. Debt covenants, credit facilities, and foreign currency exposures create financial constraints.

    Filed Feb 25, 2025
  • Ultra Clean Holdings (UCTT) FY2024 10-K risk factors
    42 risks

    Ultra Clean Holdings depends heavily on a small group of OEM customers for the majority of its semiconductor subsystem revenues.

    Filed Feb 25, 2025
  • Upbound Group (UPBD) FY2024 10-K risk factors
    56 risks

    Upbound Group faces regulatory and legal scrutiny, particularly regarding its Acima and Brigit businesses from the CFPB and FTC. The company relies heavily on proprietary algorithms and third-party bank and data partners. Consumer spending behavior and supply chain disruptions heavily influence lease-to-own operational success.

    Filed Feb 25, 2025
  • Veralto (VLTO) FY2024 10-K risk factors
    31 risks

    Veralto faces significant risks from its recent spin-off from Danaher, including potential indemnification liabilities and tax-related operating restrictions.

    Filed Feb 25, 2025
  • Valmont Industries (VMI) FY2024 10-K risk factors
    22 risks

    Valmont Industries faces significant cyclical demand in its infrastructure, utility, and agricultural markets.

    Filed Feb 25, 2025

Companies covered

4,011 companies

371 more under A